Imagen de Portada

News on sickle cell disease: Heme‐driven disordered erythropoiesis

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autor principal:	Francesca Vinchi
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	HemaSphere
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Mitochondrial retention in mature red blood cells from patients with sickle cell disease is associated with stress erythropoiesis but not with proinflammatory state
por: Marc Romana, et al.
Publicado: (2024)

Luspatercept: A peaceful revolution in the standard of care for myelodysplastic neoplasms
por: Francesca Vinchi, et al.
Publicado: (2024)

Improving CORM technology for the treatment of delayed hemolytic transfusion reaction
por: Michela Asperti, et al.
Publicado: (2024)

Erythropoiesis in health and disease: Distinguishing defective and ineffective erythropoiesis
por: Sara El Hoss, et al.
Publicado: (2026)

New approaches in gene therapy for sickle cell disease, moving in vivo
por: David G. Kent
Publicado: (2024)

Correction to “New approaches in gene therapy for sickle cell disease, moving in vivo”
Publicado: (2024)

Examining the secret life of the spleen in sickle cell disease
por: Adama Ladu, et al.
Publicado: (2025)

Inflammatory pathways and anti‐inflammatory therapies in sickle cell disease
por: Karina Tozatto‐Maio, et al.
Publicado: (2024)

Iron, arginine, and redox metabolism in peripheral blood mononuclear cells distinguishes sickle cell disease and pulmonary hypertension
por: Francesca I. Cendali, et al.
Publicado: (2026)

Can health inequalities in sickle cell disease be addressed through novel therapies?
por: Stephen P. Hibbs, et al.
Publicado: (2025)

Know your blood: Addressing barriers to preconceptual screening for sickle cell disease
por: Ernel Boadi, et al.
Publicado: (2025)

Cellular therapies for sickle cell disease: Should we be calling them a cure?
por: Lydia O. Okoibhole, et al.
Publicado: (2025)

Cerebral hemodynamics and oxygen metabolism in patients with milder and severe forms of sickle cell disease and thalassemia
por: Liza Afzali‐Hashemi, et al.
Publicado: (2024)

MMS22L is a novel key actor of normal and pathological erythropoiesis
por: Elia Colin, et al.
Publicado: (2025)

Preclinical efficacy of tasquinimod in myelodysplastic neoplasms: Restoring erythropoiesis and mitigating bone loss
por: Manja Wobus, et al.
Publicado: (2026)

Changes in the quality of life of adults with sickle cell disease following allogeneic stem cell transplantation: A mixed‐methods, prospective cohort study
por: Elisabeth Dovern, et al.
Publicado: (2025)

Elevated serum heme oxygenase‐1 in pediatric sickle cell disease: Insights from the SickleGenAfrica Network
por: Anna M. Sowa, et al.
Publicado: (2025)

Lower efficacy of transfusion of red blood cells from donors with sickle cell trait
por: Monika Dzieciatkowska, et al.
Publicado: (2026)

MeMAGEN: A Phase IIa/IIb open‐label trial of memantine testing safety and tolerability in sickle cell patients
por: Ariel Koren, et al.
Publicado: (2026)

Inhibiting the alarmin‐driven hematopoiesis‐stromal cell crosstalk in primary myelofibrosis ameliorates bone marrow fibrosis
por: Hélène F. E. Gleitz, et al.
Publicado: (2025)

Chimeric antigen receptor T‐cell therapy outcomes in T cell/histiocyte‐rich large B‐cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study
por: Mariana Bastos‐Oreiro, et al.
Publicado: (2025)

High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T‐cell therapy for large B‐cell lymphoma
por: Maeve A. O'Reilly, et al.
Publicado: (2024)

Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)‐MCL0208 clinical trial
por: Francesca Cordero, et al.
Publicado: (2026)

Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant
por: Prashant R. Tembhare, et al.
Publicado: (2024)

Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study
por: Sonia Morè, et al.
Publicado: (2025)

Inflammatory disorders in IDH‐mutated myeloid neoplasms: Characteristics and response to IDH inhibitors
por: Romain Stammler, et al.
Publicado: (2025)

Fetal‐hemoglobin‐expressing red blood cells (“F cells”) consist of three distinct types as revealed by single‐cell transcriptomic analysis of circulating reticulocytes
por: Helen Rooks, et al.
Publicado: (2025)

From hypoxia single‐cell gene signatures to HIF targeting of AML leukemic stem cells
por: Thomas Mercher, et al.
Publicado: (2024)

Correction to “Single‐cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes”
Publicado: (2024)

Minimal residual disease assessment following CD19‐targeted therapy in B‐cell precursor acute lymphoblastic leukemia using standardized 12‐color flow cytometry: A EuroFlow study
por: Martijn W. C. Verbeek, et al.
Publicado: (2025)

Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy
por: Gloria Iacoboni, et al.
Publicado: (2024)

Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype
por: Francesco Rodeghiero, et al.
Publicado: (2025)

Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma
por: Sophia Stock, et al.
Publicado: (2025)

Folate receptor beta targeting of tumor‐associated macrophages improves lymphoma cell responses to CD19 CAR T cells
por: Kerttu Kalander, et al.
Publicado: (2026)

Are we ready for disease modification in myeloproliferative neoplasms?
por: Claire N. Harrison
Publicado: (2024)

Outcomes of second‐line axicabtagene ciloleucel for large B‐cell lymphoma in the UK
por: Andrea Kuhnl, et al.
Publicado: (2026)

Bone marrow niches for hematopoietic stem cells
por: Ana Luísa Pereira, et al.
Publicado: (2024)

Outcomes and treatment patterns of patients with primary mediastinal B‐cell lymphoma after CAR‐T cell therapy failure: A DESCAR‐T analysis
por: Jean Galtier, et al.
Publicado: (2025)

Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group
por: Pierre Sesques, et al.
Publicado: (2026)

Autologous stem cell transplantation in NK/T‐cell lymphoma: Prognostic impact of EBV‐DNA in a multinational cohort—A study by the EBMT Lymphoma Working Party
por: Philipp Berning, et al.
Publicado: (2025)